JPRN-jRCT2071220112进行中（未招募）1 期
A Phase 1, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of single-dose SAR443765 in healthy adult Japanese participants
Tanaka Tomoyuki0 个研究点目标入组 12 人开始时间: 2023年2月28日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 45age old（—）
- 性别
- All
入选标准
- •Participants are eligible to be included in the study only if all of the following criteria apply:
- •- Japanese male or female participant, must be 18 to 45 years of age inclusive, at the time of signing the informed consent.
- •- Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
- •- Within 50.0 and 100.0 kg, inclusive, if male; and between 40.0 and 90.0 kg, inclusive, if female; and body mass index (BMI) within the range 18.0 and 30.0 kg/m^2 (inclusive).
- •- Contraceptive used by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding.
- •- Capable of giving signed informed consent with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •Medical conditions
- •- Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness, unless the investigator considers an abnormality to be not clinically significant.
- •- Subject has clinical signs and symptoms consistent with COVID-19, eg, fever, dry cough, dyspnea, loss of taste and smell, sore throat, fatigue or confirmed infection by appropriate laboratory test within the last 4 weeks prior to IMP administration. Subject who had severe course of COVID-19 (ie, hospitalization, extracorporeal membrane oxygenation [ECMO], mechanically ventilated).
- •- Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month).
- •- Blood donation of 400 mL within 12 weeks (male) or 16 weeks (female), 200 mL within 4 weeks or apheresis donation within 2 weeks before the first IMP administration.
- •- Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure >=30 mmHg within 3 minutes when changing from supine to standing position.
- •- Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician. Participants with a history of mild seasonal allergies might be included at Investigator's discretion.
- •Other exclusions
- •- Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究者
相似试验
进行中（未招募）
1 期
A Phase 1, open label study to evaluate the pharmacokinetics, safety and tolerability of single subcutaneous dose amlitelimab in healthy adult participants.JPRN-jRCT2071220049Tanaka Tomoyuki24
已完成
Unknown
A parallel, Phase 1, randomized, open label study to evaluate the pharmacokinetics, safety and tolerability of single subcutaneous dose amlitelimab in healthy Chinese and Japanese adult participants.KCT0008635Sanofi-Aventis Korea24
进行中（未招募）
1 期
Single-dose study of SAR441344 in healthy Chinese and Japanese participantsJPRN-jRCT2071220098Tanaka Tomoyuki36
已完成
不适用
A phase 1, two-part, randomized, open-label study to evaluate the relative bioavailability and food effect of test formulations of VX-152 and Ivacaftor in healthy subjects10038686Cystic FibrosisNL-OMON43101Vertex Pharmaceuticals30
进行中（未招募）
1 期
Effect of SARS-CoV-2 Equine Antiserum Immunoglobulin (Purified F(ab)2 fragment) in hospitalised COVID-19 patients with moderate disease.CTRI/2020/11/028779Biological ELimited